HOUSE_OVERSIGHT_028416.jpg

1"}},{"range":{"length":394,"start":0},"textstyle":" anf-ts-1"}}],"layout":"default-
body", "role":"body","text":"An examination of Celgene’s aggressive promotion of
Revlimid and its predecessor, Thalomid, while Mr. Hugin was a top executive at the
company, including its chief executive for six years, reveals many of the controversial
financial and legal tactics that have tarnished the industry’s reputation, from
marketing drugs for unapproved uses to raising prices and fighting off generic
competitors.","type":"text"},{"additions":[{"URL":"https://www.nytimes.com/2017/07/25/h
ealth/celgene-to-pay-280-million-to-settle-fraud-suit-over-cancer-
drugs.html?partner=applenews&ad-
keywords=APPLEMOBILE®ion=written through&asset id=100000006090758", "range":{"length"
:53,"start":19},"type":"link"}}],"identifier":"anf-body-
12","inlineTextStyles":[{"range":{"length":362,"start":0},"textStyle":"anf-ts-
1"}},{"range":{"length":362,"start":0},"textStyle":"anf-ts-1"}}],"layout": "default-
body", "role":"body","text":"Last year, Celgene paid $280 million to settle a whistle-
blower lawsuit claiming it had inappropriately promoted Revlimid and Thalomid to treat
a range of cancers beyond what the Food and Drug Administration had approved. Several
generic drug companies have sued the company claiming that Celgene denied them access
to drug samples needed to make cheaper
copies.","type":"text"},
{"additions":[{"URL":"https://www.youtube.com/watch?v=RIfs6hthw
Go", "range":{"length":71,"start":138},"type":"link"}}],"identifier":"anf-body-
13","inlineTextStyles":[{"range":{"length":334,"start":0},"textStyle":" anf-ts-
1"}},{"range":{"length":334,"start":0},"textStyle":" anf-ts-1"}}],"layout": "default-
body", "role":"body","text":"Mr. Hugin has also been targeted by a super PAC run by a
cancer patient taking Revlimid that launched a $1.5 million advertising campaign
criticizing steep price hikes of cancer drugs during Mr. Hugin’s tenure at Celgene.
And the Menendez campaign has attacked him around drug prices, personal profits and the
$280 million settlement.", "type":"text"}, {"bannerType":"any", "identifier":" anf-
banner_advertisement-2","layout":"ComponentLayout-
4","role": "banner advertisement", "type": "banner advertisement"}},{"identifier":" anf-
body-14","inlineTextStyles":[{"range":{"length":38,"start":0},"textStyle":" anf-ts-
1"}},{"range":{"length":38,"start":0},"textstyle":" anf-ts-1"}}],"layout": "default-
body", "role":"body","text":"Mr. Hugin has dismissed the
criticism.","type":"text"}},{"identifier":"anf-body-
15","inlineTextStyles":[{"range":{"length":317,"start":0},"textStyle":" anf-ts-
1"}},{"range":{"length":317,"start":0},"textstyle":" anf-ts-1"}}],"layout":"default-
body", "role":"body","text":"“New Jersey voters are a lot smarter than my opponent
gives them credit for,†Mr. Hugin said in a statement. “They understand that it
costs billions of dollars in research and development, and years of hard work by
hundreds of researchers and scientists, to develop medicines that successfully treat
and cure cancer.â€","type":"text"}},{"identifier":" anf-body-
16","inlineTextStyles":[{"range":{"length":237,"start":0},"textStyle":" anf-ts-
1"}},{"range":{"length":237,"start":0},"textstyle":"anf-ts-1"}}],"layout":"default-
body", "role":"body","text":"Some experts are not so sure. Patrick Murray, director of
the Monmouth University Poll, noted that despite the fact that many large drug
companies are based in New Jersey, public opinion in the state likely mirrors the
national attitude.","type":"text"}},{"identifier":"anf-body-
17","inlineTextStyles":[{"range":{"length":228,"start":0},"textStyle":"anf-ts-
1"}},{"range":{"length":228,"start":0},"textstyle":"anf-ts-1"}}],"layout":
"default-
body", "role":"body","text":"“Concern about being able to afford health care is the
top issue mentioned by voters in our polling for this year’s midterm, in large part
because of rising drug costs,†Mr. Murray said. “This provides an opening for
Menendez.’’","type":"text"}, {"components":[{"caption":"Mr. Menendez has attacked
Mr. Hugin’s record as a pharmaceutical executive, accusing him of profiting from
major price increases for cancer drugs. Bryan Anselm for The New York
Times", "captionComponent":{"text":"Mr. Menendez has attacked Mr. Hugin’s record as a
pharmaceutical executive, accusing him of profiting from major price increases for
cancer drugs. Bryan Anselm for The New York
Times"},"identifier":"100000006098032 5ba8b80411dfc","imageIdentifier":"5e5526aaedbd7af
8c8bade0a70b11da0","layout":"fullbleed-
image", "role":"photo","type":"scalable_image"}},{"identifier":"_anf-caption-
2","inlineTextStyles":[{"range":{"length":36,"start":146},"textStyle":"photo-
credit"}}],"layout": "default-caption", "role":"caption","text":"Mr. Menendez has attacked
Mr. Hugin’s record as a pharmaceutical executive, accusing him of profiting from
major price increases for cancer drugs. Bryan Anselm for The New York Times
","type":"text"}}],"identifier":"anf-container-1","layout":"image-
container","role":"container","type":"container"}}, {"identifier":" anf-body-
18","inlineTextStyles":[{"range":{"length":277,"start":0},"textStyle":"_anf-ts-

HOUSE_OVERSIGHT_028416